First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
Add-On To Schizophrenia, Bipolar Depression Indications
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.
